Board Changes
TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach ...
2 ASX ‘buy the dip’ candidates with moats
Companies of above-average quality don’t trade cheaply too often. When they do, it’s usually because investors are concerned ...
CSL Limited: Divergent Outlook For Its 2 Key Businesses
I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring ...
Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected
TURKU, FI / ACCESS Newswire / March 20, 2025 /Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the ...
CSL is approaching a 5-year low. Is this a buying opportunity?
CSL Ltd (ASX: CSL) shares have been sold off recently and are down near multi-year lows. Is now the time to buy?
A quality ASX 200 share with 'limited to no impact' from Donald Trump's tariffs
Looking for an oversold S&P/ASX 200 Index (ASX: XJO) share that’s relatively immune to Donald Trump’s tariffs? You’ll want to ...
pharmaphorum6d
CSL Vifor offers campaign to mollify EC in antitrust probe
CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.